24/7 Market News Snapshot 05 June, 2025 – Clearmind Medicine Inc. Common Shares (NASDAQ:CMND)

June 5, 2025

DENVER, Colo., 05 June, 2025 (www.247marketnews.com) – (Nasdaq:CMND) are discussed in this article.
Clearmind Medicine Inc. (Nasdaq:CMND) is witnessing significant market activity as its stock surges approximately 14.48% to trade at $1.035, up from the previous close of $0.904. Opening at $0.913, this upward momentum reflects heightened investor interest, with a trading volume of 648.86K shares. Analysts suggest the stock may face support around the $1.00 level with resistance potentially at $1.05, indicating a promising short-term outlook for traders monitoring this trend.

Simultaneously, Clearmind is advancing its clinical initiatives as the company has announced the enrollment of its first patient in a Phase I/IIa clinical trial for CMND-100, an innovative oral drug candidate based on MEAI, aimed at addressing Alcohol Use Disorder (AUD). This condition remains a significant public health concern, affecting millions worldwide with limited treatment options available.

The pioneering Phase I/IIa study is being conducted at a distinguished medical facility recognized for its Department of Psychiatry. It is tailored to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100 while assessing its preliminary efficacy in reducing alcohol cravings and consumption among participants. The trial opens its doors to both treatment-seeking individuals diagnosed with AUD and non-treatment-seeking individuals who have reported significant binge drinking activities.

Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, highlighted the significance of this milestone, noting that the first patient enrollment represents an important step in creating effective therapies for those struggling with AUD. He emphasized the potential transformative impact of CMND-100 in bridging the gaps within current treatment frameworks. With a robust portfolio of 31 granted patents across 19 families, Clearmind is committed to innovating in the field of mental health, aiming to lead advancements in psychedelic therapies.

Related news for (CMND)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.